DaVita Inc. 2005 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2005. DaVita Inc. is a leading provider of dialysis services in the United States for patients with end-stage renal disease (ESRD). As of year-end, the company operated or provided administrative services to approximately 1,233 outpatient dialysis centers in 41 states and the District of Columbia, serving approximately 96,000 patients. The company also provides acute inpatient dialysis services in approximately 795 hospitals.
The reporting period was defined by the completion of the acquisition of DVA Renal Healthcare, Inc. (formerly Gambro Healthcare) on October 5, 2005, for approximately $3.06 billion. This acquisition added 566 centers and 43,000 patients. To satisfy Federal Trade Commission requirements, DaVita divested 71 centers during the year, with results from these divested centers reported as discontinued operations.
Key Financial Metrics
| Metric | 2005 | 2004 |
|---|---|---|
| Net Operating Revenues | $2,973.9 million | $2,177.3 million |
| Operating Income | $465.4 million | $381.1 million |
| Net Income | $228.6 million | $222.3 million |
| Diluted EPS (Continuing Ops) | $1.99 | $1.99 |
| Operating Cash Flow | $485.6 million | $419.9 million |
| Long-Term Debt | $4,085.4 million | $1,322.5 million |
| Total Assets | $6,279.8 million | $2,512.0 million |
| Working Capital | $664.7 million | $427.0 million |
Margins: Operating income margin for continuing operations was approximately 15.5% in 2005, down from 17.2% in 2004, primarily due to higher labor costs and the integration of DVA Renal Healthcare. Average revenue per treatment remained stable at $313 for both 2005 and 2004.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 37% year-over-year. Approximately 22% of this increase was attributable to the DVA Renal Healthcare acquisition, while the remainder was driven by a 36% increase in treatment volume and stable revenue per treatment.
- Debt Structure: Long-term debt increased significantly to $4.1 billion from $1.3 billion to finance the DVA acquisition. The company entered into a new $3.05 billion credit facility and issued $1.35 billion in senior and senior subordinated notes.
- Discontinued Operations: The company recorded a gain of $8.1 million on the disposal of discontinued operations (divested centers) and recognized $13.2 million in income from these operations.
- Acquisition Costs: The company incurred approximately $29 million in acquisition-related costs and $11 million in integration costs in the fourth quarter of 2005.
Guidance, Outlook, and Risks
2006 Outlook: Management targets operating income for 2006 in the range of $630 million to $700 million, excluding the impact of FASB No. 123R (stock-based compensation). Pre-tax stock option expense is expected to be between $20 million and $30 million. Operating cash flow is projected to be between $410 million and $480 million.
Key Risks and Contingencies:
- Regulatory Investigations: The company is cooperating with multiple subpoenas from U.S. Attorney's Offices (Missouri, New York, Pennsylvania) regarding billing practices, financial relationships with physicians, and pharmaceutical administration. No proceedings have been initiated, but negative findings could result in substantial penalties or exclusion from Medicare/Medicaid.
- Payment Rates: Approximately 65% of revenue comes from government programs (Medicare/Medicaid). Rates are fixed and subject to potential reductions or lack of inflation adjustments. Commercial rates are under negotiation pressure.
- Pharmaceutical Dependency: Approximately 35% of revenue is tied to pharmaceuticals, primarily EPO. The company relies on a single supplier (Amgen) and faces risks regarding pricing, supply interruptions, and the introduction of new drugs like Aranesp.
- Integration Risks: Successful integration of DVA Renal Healthcare is critical. Challenges include system integration, billing collection performance, and retaining medical directors.
Investor Verification Checklist
- Verify the status of ongoing government investigations (Missouri, New York, Pennsylvania) and potential financial exposure.
- Monitor the integration progress of DVA Renal Healthcare, specifically billing collection rates and medical director retention.
- Track changes in Medicare payment policies, particularly regarding EPO reimbursement and the composite rate adjustments effective in 2006.
- Assess the impact of the 10-year supply agreement with Gambro on future cost structures and margins.
- Review the company's ability to service its increased debt load ($4.1 billion) and maintain required financial covenants.